Remove

PTC/SBr08a (08-03)
Approved for use through 07/31/2008 ONS 0851-0331
U.S. Peterol and Trademark Office, U.S. DEPARTMENT OF COMMERCE It to a collection of information unless it contains a valid OMS control number.

	Application Number		105/9/12
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Filing Date		2007-01-03
	First Named Inventor	STAN	ILEY, EDOUARD GUY
	Art Unit		
	Examiner Name		
	Attorney Docket Number		ASCC-004

U.S. PATENTS

Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue D	late	Name of Patentee or Applicant Relevant		c,Columns,Lines where ant Passages or Relevant as Appear			
	1	5635386		1997-06	-03	Paisson et al.					
	2	6280718		2001-08	-28	Kaufman et al					
If you wisl	h to a	dd additional U.S. Pate	nt citatio	n inform	ation pl	ease click the	Add button.		Add		
			U.S.P	ATENT	APPLIC	CATION PUB	LICATIONS		Remove		
Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publica Date	tion	Name of Patentee or Applicant Releva			ges,Columns,Lines where evant Passages or Relevant ures Appear		
	1	20040224403		2004-11	-11	Bhatia					
If you wis	h to a	dd additional U.S. Publ	ished Ar	olication	citation	n information	please click the Ado	d button	Add		_
,						ENT DOCUM			Remove		_
Examiner Initial*	Cite No	Foreign Document Number ³	Countr Code ²		Kind Code4		Name of Patente Applicant of cited Document	e or	here Rele	r Relevant	T6
	1	1344819	ΕP			2003-09-17	Novartis AG				
	2	WO03050251	wo			2003-06-19	Geron Corporation				

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

F

E

Application Number		10579712	
Filing Date		2007-01-03	
First Named Inventor	STANLEY, EDOUARD GUY		
Art Unit			
Examiner Name			
Attorney Docket Number		ASCC-004	

,		dd additional Foreign Patent Document citation information please click the Add button	
		NON-PATENT LITERATURE DOCUMENTS	Remove
Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropris (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issi publisher, city and/or country where published.	
	1	CHADWICK et al., "Cytokines and BMP-4 promote hematopoietic differentiation of human embr Blood, 102(3):906-915 (August 2003)	ryonic stem cells*
	2	KAUFMAN et al., "Hematopoieto colory-forming cells derived from human embryonic stem cells USA, 98(19):10716-10721 (September 11, 2001)	s" Proc. Natl. Acad. Sci
	3	DANG et al., "Efficiency of Embryoid Body Formation and Hematopoietic Development from Em Different Culture Systems" Biotechnology and Bioengineering, 78(4):442-453 (May 20, 2002)	nbryonic Stem Cells in
	4	DESBAILLETS et al., "Special Review Series - Gene Manipulation and Integrative Physiology" (8):645-651 (2000)	Exp. Physiol., 85
If you wis	h to a	 dd additional non-patent literature document citation information please click the Add bu	utton Add
		EXAMINER SIGNATURE	
Examiner	Signa	ature Date Considered	

1 See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. 2 Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). 3 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the sensi number of the patent document. Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 5 Applicant is to place a check mark here if English language translation is attached.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		10579712
Filing Date		2007-01-03
First Named Inventor STAN		ILEY, EDOUARD GUY
Art Unit		
Examiner Name		
Attornou Docket Number		ASCC 004

CERTIFICATION STATEMENT

Please see 37	CFR 1.97 an	1.98 to make the ap	propriate selection(s):
---------------	-------------	---------------------	-------------------------

That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patient office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. Sea 37 CFF 1.37(e)(1).

OR

That no item of information contained in the information disclosure statement was cited in a communication from a foreign parter office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquity, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 159(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 1379(c).

- See attached certification statement.
- Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.

Karl Bozicevic

Name/Print

SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

Registration Number

28.807

Toma or the organization			
Signature	/Karl Bozicevic/	Date (YYYY-MM-DD)	2007-01-03

This collection of information is required by 3T CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is for life railed by the USPTO to process) an application. Confidentiality is governed by \$5 U.S. C. 12.0 and 37 CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application from the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete his form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Tradenary Cfiling. U.S. Operatment of Commence, P. 0. Box 1450, Alexandrin, V.S. 2313-1450. D. ONT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandrin, V.S. 2313-1450.

Privacy Act Statement

The Privacy Act of 1974 (P. L. 93-579) requires that you be given certain information in connection with your submission of the stackhold from related to a patient application or patient. Accordingly, pursuant to the requirements of the Act, places be advised that (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) familishing of the information solicided is couldrain; and (3) the primoral pursuance for which the information is used by the U.S. Patient and Trademan Coffice is to process and/or examine your submission related to a patient agricultant or patient. If you do not furnish the requested process and/or examine your submission related to a patient agricultant or patient. If you do not furnish the requested results of the patient of the patient and the patient of the patient

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.
 - A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiation.
 - A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
 - A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552(m).
 - A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
 may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
 to the Patent Cooperation Treaty.
 - A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
 - 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designed, uturing an insection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 4d U.S.C. 2904 and 2905. Such disclosure shall be made in accordance with the GSA requisions governing inseption of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
- A record from this system of records may be disclosed, as a routine use, to the public after either publication of the
 application pursuant to 35 U.S.C. 12(2) or issuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be
 disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filled in application
 which became abandoned or in which the proceedings were terminated and which application is referenced by either a
 published application, an application open to public inspections or as issued patent.
 - A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.